ライフサイエンスコーパス: mucinous neoplasm

1 otential (for example, intraductal papillary mucinous neoplasms).

2 ement of patients with Intraductal Papillary Mucinous Neoplasms.

3 the mouse pancreas and prevents formation of mucinous neoplasms.

4 use pancreas to induce intraductal papillary mucinous neoplasms.

5 s on the treatment of intraductal pancreatic mucinous neoplasms.

6 adenocarcinoma, 17 had intraductal papillary mucinous neoplasms, 26 had symptomatic chronic pancreati

7 ndocrine tumors (35%), intraductal papillary mucinous neoplasms (33%), solid pseudopapillary neoplasm

8 amples of 169 PCLs (90 intraductal papillary mucinous neoplasms, 43 mucinous cystic neoplasms, and 36

9 s cystic neoplasm =16, intraductal papillary mucinous neoplasm = 5, neuroendocrine tumors = 4), or 10

10 = 4), or 10 malignant (intraductal papillary mucinous neoplasm = 7, cystadenocarcinomas = 3) lesions.

11 compared with invasive intraductal papillary mucinous neoplasm (84.5% vs. 36%; P < 0.001).

12 carcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) and pancreatic ductal adenoc

13 28, borderline 7), 22 intraductal papillary mucinous neoplasms (adenoma 9, borderline 9, cancer 4),

14 s for the treatment of intraductal papillary mucinous neoplasm and cystic lesions of the pancreas app

15 Intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumor bi

16 esection of pancreatic intraductal papillary mucinous neoplasm and to correlate recurrence and surviv

17 ntified in 85 HRIs (82 intraductal papillary mucinous neoplasms and 3 pancreatic endocrine tumors).

18 asia in less than 3 cm intraductal papillary mucinous neoplasms and in multiple intraepithelial neopl

19 ucinous cysts, such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, have t

20 leads to predominantly intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, while

21 rs, two Brenner tumors not associated with a mucinous neoplasm, and two atypical proliferative (borde

22 omas, 23 as noninvasive proliferative cystic mucinous neoplasms, and only 7 as cystadenocarcinomas.

23 us cystic neoplasm and intraductal papillary mucinous neoplasm are superior to the original 2006 guid

24 More cases of intraductal papillary mucinous neoplasms are being diagnosed and studied.

25 endocrine tumors, and intraductal pancreatic mucinous neoplasms are included.

26 Intraductal papillary mucinous neoplasms are increasingly diagnosed cystic pre

27 Intraductal papillary mucinous neoplasms are the most common pancreatic malign

28 n subtype, branch-duct intraductal papillary mucinous neoplasms, are not clearly established.

29 lassified 113 resected intraductal papillary mucinous neoplasms as invasive carcinoma (n = 40) or as

30 tations, and high-risk intraductal papillary mucinous neoplasm, as they are at high risk of developin

31 e commonly detected in intraductal papillary mucinous neoplasm-associated PDACs.

32 ho underwent "curative" resection for cystic mucinous neoplasms at Mayo Clinic Rochester from 1940 to

33 (</=30 mm) branch-duct intraductal papillary mucinous neoplasm (BD IPMN; 67%), whereas also being spe

34 ients with branch duct intraductal papillary mucinous neoplasms (BD-IPMN) are offered indefinite surv

35 f low-risk branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) has not been established y

36 cially for branch duct intraductal papillary mucinous neoplasms (BD-IPMNs), remain uncertain.

37 lopment of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

38 ology should be retained for both serous and mucinous neoplasms because of the risk of extraovarian i

39 Intraductal papillary mucinous neoplasms can be multifocal and a potential cau

40 nous cystic neoplasms, intraductal papillary mucinous neoplasm, cystic neuroendocrine tumors, and cys

41 inous cystic neoplasms+intraductal papillary mucinous neoplasms) from benign cystic lesions (serous c

42 ly one patient with an intraductal papillary mucinous neoplasm had high-grade dysplasia.

43 bute to progression of intraductal papillary mucinous neoplasms into malignancies.

44 for the management of intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm we

45 e relationship between intraductal papillary mucinous neoplasm (IPMN) and the developmental ductal va

46 nt of branch duct (BD) intraductal papillary mucinous neoplasm (IPMN) espouse safety of observation o

47 ic duct (MPD)-involved intraductal papillary mucinous neoplasm (IPMN) has been established by surgica

48 eatic branch-duct (BD) intraductal papillary mucinous neoplasm (IPMN) is infrequent and that extrapan

49 re similar to those of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.

50 neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions.

51 The existing Intraductal Papillary Mucinous Neoplasm (IPMN) risk stratification relies on c

52 Human intraductal papillary mucinous neoplasm (IPMN) specimens were analyzed by immu

53 tic lesions resembling intraductal papillary mucinous neoplasm (IPMN) were observed as early as 2 mon

54 itis (CP), 71 PDAC, 70 intraductal papillary mucinous neoplasm (IPMN), 16 mucinous cystic neoplasm (M

55 s preneoplastic lesion intraductal papillary mucinous neoplasm (IPMN), to find new microRNA (miRNA)-b

56 Intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer is ty

57 ronic pancreatitis and intraductal papillary mucinous neoplasm (IPMN).

58 carcinoma arising from intraductal papillary mucinous neoplasm (IPMN).

59 inoma in patients with intraductal papillary mucinous neoplasm (IPMN).

60 ncreatic resection for intraductal papillary mucinous neoplasm (IPMN).

61 logic heterogeneity of intraductal papillary mucinous neoplasms (IPMN) complicates the prediction of

62 population of resected intraductal papillary mucinous neoplasms (IPMN) of the pancreas with respect t

63 for the management of intraductal papillary mucinous neoplasms (IPMN) recommend surgical treatment i

64 section for pancreatic intraductal papillary mucinous neoplasms (IPMN) using targeted next-generation

65 (PDAC) may arise from intraductal papillary mucinous neoplasms (IPMN) with malignant transformation,

66 s, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas, 1 low-grad

67 creatoduodenectomy for intraductal papillary mucinous neoplasms (IPMN).

68 e origin of pancreatic intraductal papillary mucinous neoplasms (IPMN).

69 mors (PanNET, n = 42), intraductal papillary mucinous neoplasms (IPMN, n = 20), and ampulla of Vater

70 ignant mucinous cysts (intraductal papillary mucinous neoplasm [IPMN], mucinous cystic neoplasm [MCN]

71 ations are reported in intraductal papillary mucinous neoplasms (IPMNs) and in McCune-Albright syndro

72 Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms

73 AC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their patho

74 Among PCNs, Intraductal Papillary Mucinous Neoplasms (IPMNs) are common lesions that may p

75 Pancreatic intraductal papillary mucinous neoplasms (IPMNs) are grossly visible (typicall

76 Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cysts that can

77 Intraductal papillary mucinous neoplasms (IPMNs) are the most frequent cystic

78 iagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involving the main duct (MD I

79 e and branch-duct (BD) intraductal papillary mucinous neoplasms (IPMNs) is important to understand th

80 e growing awareness of intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas among clinici

81 Intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas are ideal neo

82 radiographic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the pancreas are identifie

83 Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in br

84 molecular pathology of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas has not been

85 Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas have been sug

86 ed in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

87 The natural history of intraductal papillary mucinous neoplasms (IPMNs) remains uncertain.

88 glycoproteins from 64 intraductal papillary mucinous neoplasms (IPMNs), 55 cyst fluid samples, 104 p

89 increased detection of intraductal papillary mucinous neoplasms (IPMNs), and their management remains

90 s cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (M

91 eling of patients with intraductal papillary mucinous neoplasms (IPMNs).

92 elines for branch-duct intraductal papillary mucinous neoplasms (IPMNs).

93 If the mucinous neoplasm is minimally invasive and cytoreductio

94 Some cysts, such as intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, and cysti

95 Pancreatic cysts may be intraductal mucinous neoplasms, mucinous cystic neoplasms, serous cy

96 ucosal hyperplasia and low-grade appendiceal mucinous neoplasm (n = 17), and those with malignant muc

97 stic neoplasms (n=17), intraductal papillary mucinous neoplasms (n=15), serous cystadenomas (n=12), o

98 er, the progression of intraductal papillary mucinous neoplasm of the pancreas (IPMN) in this populat

99 Mucinous neoplasms of the appendix were found in 5 of 17

100 Intraductal papillary mucinous neoplasms of the bile duct are premalignant les

101 lasms of the liver and intraductal papillary mucinous neoplasms of the bile duct.

102 Mucinous neoplasms of the gastrointestinal tract are cha

103 e of CBD dilatation in Intraductal Papillary Mucinous Neoplasms of the pancreas (IPMN) among patients

104 carcinomas arising in intraductal papillary mucinous neoplasms of the pancreas (IPMN) by histologica

105 Intraductal papillary mucinous neoplasms of the pancreas are being recognized

106 Current understanding is that all cystic mucinous neoplasms of the pancreas are potentially malig

107 f 84 patients (70 women, 14 men) with cystic mucinous neoplasms of the pancreas, 54 were classified a

108 Mucinous (intraductal mucinous neoplasm or mucinous cystic neoplasm) lesions h

109 esions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial

110 Intraductal papillary mucinous neoplasm (particularly the branch duct variant)

111 Intraductal papillary mucinous neoplasm patients appear to have cancer risk in

112 (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02).

113 In invasive intraductal papillary mucinous neoplasm, recurrence was similar after partial

114 Invasive intraductal papillary mucinous neoplasm recurs frequently even after a complet

115 contrast, noninvasive intraductal papillary mucinous neoplasm recurs infrequently after resection, a

116 a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%) than non-

117 itonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous d

118 Intraductal papillary mucinous neoplasms represent a distinct clinicopathologi

119 s of the treatment of intraductal pancreatic mucinous neoplasms shed some light on the management of

120 Appendiceal mucinous neoplasms sometimes present with peritoneal dis

121 fluid from pancreatic intraductal papillary mucinous neoplasms, the monoclonal antibody Das-1 identi

122 Smad4 both regulate an intraductal papillary mucinous neoplasm-to-PDAC sequence through distinct tumo

123 g malignant pancreatic intraductal papillary mucinous neoplasms were developed based on logistic regr

124 sor neoplasms, such as intraductal papillary mucinous neoplasms with high-grade dysplasia and some en

125 ia, or intestinal-type intraductal papillary mucinous neoplasms with intermediate-grade dysplasia.

126 ative R0 microinvasive intraductal papillary mucinous neoplasms (without recurrence at 27, 29, and 34